Kodiak Sciences Inc

Stage 2 · Advancing · week 4

As of Oct 22, 2026, Kodiak Sciences is in Stage 2, the uptrend phase, now in week 4 (since Sep 30, 2026). It closed at $85.78, 14.1% below its 52-week high and above its 200-day average, which is rising.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. More about the company

$85.78

-2.21% today

$5.4B · Mid cap

Market Neutral — Fading

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is KOD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S2 30w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 15w → S1 12w → S2 8w → S3 8w → S4 13w → S1 1w → S4 4w → S1 4w → S2 13w → S3 6w → S4 9w → S1 10w → S2 30w → S3 3w → S2 12w → S3 6w → S2 6w → S3 2w → S2 3w current

Total tracked: 166 weeks across 19 stage runs.

KOD among Biotechnology6th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%

vs 52W High

-14.1%

$16.90 lo$99.87 hi

14.1% below 52W high, pullback range

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 4

1w13w26w

Week 4, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

113.9%

200 DMA: $40.10 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.30x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↑

Short-term trend rising strongly

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+172.1%

+107.1%

+89.7%

YTD

+229.7%

+351.5%

Scan Membership

Breakout Watch

Latest: 2024-11-22

7 appearances in last 60 days. First seen: 2019-07-23.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 4 · Vol 0.30x

2026-10-21S2

Wk 4 · Vol 0.41x

2026-10-20S2

Wk 3 · Vol 0.44x

2026-10-19S2

Wk 3 · Vol 0.53x

2026-10-16S2

Wk 3 · Vol 0.57x

2026-10-15S2

Wk 3 · Vol 0.72x

2026-10-14S2

Wk 3 · Vol 1.26x

2026-10-13S2

Wk 2 · Vol 0.81x

2026-10-12S2

Wk 2 · Vol 0.71x

2026-10-09S2

Wk 2 · Vol 0.94x

2026-10-08S2

Wk 2 · Vol 0.83x

2026-10-07S2

Wk 2 · Vol 0.72x

Moving averages & range

50 DMA

$57.28

200 DMA

$40.10

52W High

$99.87

52W Low

$16.90

5D Low

$85.75

Resistance levels (recent highs)

20d High

$99.87

60d High

$99.87

120d High

$99.87

250d High

$99.87

Next resistance

+16.4%

to 20d High

ROE

-368.4%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 88.1

Kodiak Sciences: quick answers

What stage is Kodiak Sciences in?

As of Oct 22, 2026, Kodiak Sciences (KOD) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 30, 2026 and is in week 4. What the four stages mean

Is Kodiak Sciences in an uptrend?

Yes. Kodiak Sciences is in a Stage 2 uptrend. It trades 113.9% above its 200-day average, which is rising.

How far is Kodiak Sciences from its 52-week high?

Kodiak Sciences closed at $85.78 on Oct 22, 2026, 14.1% below its 52-week high of $99.87. Its 52-week low is $16.90.

How has Kodiak Sciences performed over the past year?

As of Oct 22, 2026, Kodiak Sciences is up 351.5% over the past year and up 229.7% so far in 2026.

Which sector and industry is Kodiak Sciences in?

Kodiak Sciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.